131 related articles for article (PubMed ID: 22231975)
1. Diabetes mellitus in a cohort of patients with acromegaly.
Rodrigues TC; Costenaro F; Fedrizzi D; Oliveira MD; Lima PB; Boschi V; Czepielewski MA
Arq Bras Endocrinol Metabol; 2011 Dec; 55(9):714-9. PubMed ID: 22231975
[TBL] [Abstract][Full Text] [Related]
2. Low serum IGF-I/GH ratio is associated with abnormal glucose tolerance in acromegaly.
Fukuoka H; Takahashi Y; Iida K; Kudo T; Nishizawa H; Imanaka M; Takeno R; Iguchi G; Takahashi K; Okimura Y; Kaji H; Chihara K
Horm Res; 2008; 69(3):165-71. PubMed ID: 18219220
[TBL] [Abstract][Full Text] [Related]
3. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy.
Colao A; Baldelli R; Marzullo P; Ferretti E; Ferone D; Gargiulo P; Petretta M; Tamburrano G; Lombardi G; Liuzzi A
J Clin Endocrinol Metab; 2000 Jan; 85(1):193-9. PubMed ID: 10634386
[TBL] [Abstract][Full Text] [Related]
4. Insulin resistance and insulin secretion in non-diabetic acromegalic patients.
Coculescu M; Niculescu D; Lichiardopol R; Purice M
Exp Clin Endocrinol Diabetes; 2007 May; 115(5):308-16. PubMed ID: 17516294
[TBL] [Abstract][Full Text] [Related]
5. [Cardiac morphology and performance alterations and analysis of determinant factors of left ventricular hypertrophy in 40 patients with acromegaly].
Casini AF; Araújo PB; Fontes R; Xavier SS; Gadelha MR
Arq Bras Endocrinol Metabol; 2006 Feb; 50(1):82-90. PubMed ID: 16628279
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of serum GH, IGF-1 and IGFBP3 in patients of acromegaly with uncontrolled diabetes: a pilot study.
Dutta P; Singhal S; Sachdeva NK; Shah VN; Pathak A; Mukherjee KK; Bhansali A
J Assoc Physicians India; 2014 Aug; 62(8):686-90. PubMed ID: 25856936
[TBL] [Abstract][Full Text] [Related]
7. Discordant biological parameters of remission in acromegaly do not increase the risk of hypertension or diabetes: a study with the Liege Acromegaly Survey database.
Amodru V; Petrossians P; Colao A; Delemer B; Maione L; Neggers SJCMM; Decoudier B; Kamenicky P; Castinetti F; Hana V; Pivonello R; Carvalho D; Brue T; Beckers A; Chanson P; Cuny T
Endocrine; 2020 Oct; 70(1):134-142. PubMed ID: 32562181
[TBL] [Abstract][Full Text] [Related]
8. Hypertension in acromegaly and in the normal population: prevalence and determinants.
Vitale G; Pivonello R; Auriemma RS; Guerra E; Milone F; Savastano S; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2005 Oct; 63(4):470-6. PubMed ID: 16181242
[TBL] [Abstract][Full Text] [Related]
9. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
10. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment.
Colao A; Terzolo M; Bondanelli M; Galderisi M; Vitale G; Reimondo G; Ambrosio MR; Pivonello R; Lombardi G; Angeli A; degli Uberti EC
Clin Endocrinol (Oxf); 2008 Oct; 69(4):613-20. PubMed ID: 18410555
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone and insulin-like growth factor-1 in blood and urine as response markers during treatment of acromegaly with octreotide: a double-blind placebo-controlled study.
Fredstorp L; Werner S
J Endocrinol Invest; 1993 Apr; 16(4):253-8. PubMed ID: 8514980
[TBL] [Abstract][Full Text] [Related]
12. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy.
Ho KY; Weissberger AJ
Clin Endocrinol (Oxf); 1994 Jul; 41(1):75-83. PubMed ID: 8050134
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients.
Charalampaki P; Hildebrandt G; Schaeffer HJ; Schönau E; Klug N
Exp Clin Endocrinol Diabetes; 1998; 106(2):130-4. PubMed ID: 9628244
[TBL] [Abstract][Full Text] [Related]
14. Serum insulin-like growth factor-I concentration in cats with diabetes mellitus and acromegaly.
Berg RI; Nelson RW; Feldman EC; Kass PH; Pollard R; Refsal KR
J Vet Intern Med; 2007; 21(5):892-8. PubMed ID: 17939540
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
[TBL] [Abstract][Full Text] [Related]
16. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry.
Fieffe S; Morange I; Petrossians P; Chanson P; Rohmer V; Cortet C; Borson-Chazot F; Brue T; Delemer B;
Eur J Endocrinol; 2011 Jun; 164(6):877-84. PubMed ID: 21464140
[TBL] [Abstract][Full Text] [Related]
17. Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly.
Parkinson C; Renehan AG; Ryder WD; O'Dwyer ST; Shalet SM; Trainer PJ
Clin Endocrinol (Oxf); 2002 Jul; 57(1):59-64. PubMed ID: 12100070
[TBL] [Abstract][Full Text] [Related]
18. Glycemic profile in patients with acromegaly treated with somatostatin analogue.
Valea A; Carsote M; Ghervan C; Georgescu C
J Med Life; 2015; 8 Spec Issue(Spec Issue):82-6. PubMed ID: 26361517
[TBL] [Abstract][Full Text] [Related]
19. Homocysteine levels in acromegaly patients.
Hekimsoy Z; Ozmen B; Ulusoy S
Neuro Endocrinol Lett; 2005 Dec; 26(6):811-4. PubMed ID: 16380700
[TBL] [Abstract][Full Text] [Related]
20. Increased Serum Sclerostin Levels in Patients With Active Acromegaly.
Pekkolay Z; Kılınç F; Gozel N; Önalan E; Tuzcu AK
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31821453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
